These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 38616571)

  • 1. Empirically contrasting urine drug screening-based opioid use disorder treatment outcome definitions.
    Brandt L; Odom GJ; Hu MC; Castro C; Balise RR;
    Addiction; 2024 Jul; 119(7):1289-1300. PubMed ID: 38616571
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gender-specific predictors of methadone treatment outcomes among African Americans at an urban clinic.
    Lister JJ; Brown S; Greenwald MK; Ledgerwood DM
    Subst Abus; 2019; 40(2):185-193. PubMed ID: 30888262
    [No Abstract]   [Full Text] [Related]  

  • 4. Study protocol of the ESUB-MG cluster randomized trial: a pragmatic trial assessing the implementation of urine drug screening in general practice for buprenorphine maintained patients.
    ESUB-MG Study Group
    BMC Fam Pract; 2016 Mar; 17():24. PubMed ID: 26931763
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-world use and clinical outcomes after 24 weeks of treatment with a prescription digital therapeutic for opioid use disorder.
    Maricich YA; Gerwien R; Kuo A; Malone DC; Velez FF
    Hosp Pract (1995); 2021 Dec; 49(5):348-355. PubMed ID: 34461801
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Baseline risk factors for drug use among African-American patients during first-month induction/stabilization on methadone.
    Lister JJ; Greenwald MK; Ledgerwood DM
    J Subst Abuse Treat; 2017 Jul; 78():15-21. PubMed ID: 28554598
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessing drug use during follow-up: direct comparison of candidate outcome definitions in pooled analyses of addiction treatment studies.
    Korte JE; Magruder KM; Chiuzan CC; Logan SL; Killeen T; Bandyopadhyay D; Brady KT
    Am J Drug Alcohol Abuse; 2011 Sep; 37(5):358-66. PubMed ID: 21854278
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-world evidence for a prescription digital therapeutic to treat opioid use disorder.
    Maricich YA; Xiong X; Gerwien R; Kuo A; Velez F; Imbert B; Boyer K; Luderer HF; Braun S; Williams K
    Curr Med Res Opin; 2021 Feb; 37(2):175-183. PubMed ID: 33140981
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Descriptive analysis of urine drug screen results in patients with opioid use disorder managed in a primary care setting.
    Sobel HG; Warrington JS; Francis-Fath S; Crocker AM; Berger CA
    Addict Sci Clin Pract; 2021 Sep; 16(1):59. PubMed ID: 34593036
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Extended-release naltrexone versus standard oral naltrexone versus placebo for opioid use disorder: the NEAT three-arm RCT.
    Strang J; Kelleher M; Mayet S; Day E; Hellier J; Byford S; Murphy C; McLennan B; Shearer J; Ryan E; Marsden J
    Health Technol Assess; 2019 Jan; 23(3):1-72. PubMed ID: 30702059
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Individual-Level Risk Prediction of Return to Use During Opioid Use Disorder Treatment.
    Luo SX; Feaster DJ; Liu Y; Balise RR; Hu MC; Bouzoubaa L; Odom GJ; Brandt L; Pan Y; Hser YI; VanVeldhuisen P; Castillo F; Calderon AR; Rotrosen J; Saxon AJ; Weiss RD; Wall M; Nunes EV
    JAMA Psychiatry; 2024 Jan; 81(1):45-56. PubMed ID: 37792357
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Are patients' goals in treatment associated with expected treatment outcomes? Findings from a mixed-methods study on outpatient pharmacological treatment for opioid use disorder.
    Rosic T; Naji L; Panesar B; Chai DB; Sanger N; Dennis BB; Marsh DC; Rieb L; Worster A; Thabane L; Samaan Z
    BMJ Open; 2021 Jan; 11(1):e044017. PubMed ID: 33436476
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Associations Between Buprenorphine\Naloxone and Methadone Treatment and non-Opioid Substance Use in Prescription-Type Opioid Use Disorder: Secondary Analyses From the OPTIMA Study: Associations entre le traitement avec la buprénorphine/naloxone et avec la méthadone et l'utilisation de substances non opioïdes dans le trouble lié à l'usage d'opioïdes de type sur ordonnance : analyses secondaires de l'étude OPTIMA.
    Bakouni H; Sharafi H; Drouin S; Fortin R; Marsan S; Brissette S; Socias ME; Le Foll B; Lim R; Jutras-Aswad D
    Can J Psychiatry; 2024 Apr; 69(4):252-263. PubMed ID: 37899716
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is telemedicine the answer to rural expansion of medication treatment for opioid use disorder? Early experiences in the feasibility study phase of a National Drug Abuse Treatment Clinical Trials Network Trial.
    Hser YI; Ober AJ; Dopp AR; Lin C; Osterhage KP; Clingan SE; Mooney LJ; Curtis ME; Marsch LA; McLeman B; Hichborn E; Lester LS; Baldwin LM; Liu Y; Jacobs P; Saxon AJ
    Addict Sci Clin Pract; 2021 Apr; 16(1):24. PubMed ID: 33879260
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prior National Drug Abuse Treatment Clinical Trials Network (CTN) opioid use disorder trials as background and rationale for NIDA CTN-0100 "optimizing retention, duration and discontinuation strategies for opioid use disorder pharmacotherapy (RDD)".
    Shulman M; Weiss R; Rotrosen J; Novo P; Costello E; Nunes EV
    Addict Sci Clin Pract; 2021 Mar; 16(1):15. PubMed ID: 33676577
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Self-report and urine drug screen concordance among women with co-occurring PTSD and substance use disorders participating in a clinical trial: Impact of drug type and participant characteristics.
    Ruglass LM; Shevorykin A; Zhao Y; Killeen TK; Bauer AG; Morgan-López AA; Back SE; Fitzpatrick S; López-Castro T; Norman SB; Saavedra LM; Hien DA
    Drug Alcohol Depend; 2023 Mar; 244():109769. PubMed ID: 36696843
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trends in Urine Drug Monitoring Among Persons Receiving Long-Term Opioids and Persons with Opioid Use Disorder in the United States.
    Sohn M; Talbert JC; Huang Z; Oser C; Freeman PR
    Pain Physician; 2021 Mar; 24(2):E249-E256. PubMed ID: 33740362
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Power of automated algorithms for combining time-line follow-back and urine drug screening test results in stimulant-abuse clinical trials.
    Oden NL; VanVeldhuisen PC; Wakim PG; Trivedi MH; Somoza E; Lewis D
    Am J Drug Alcohol Abuse; 2011 Sep; 37(5):350-7. PubMed ID: 21854277
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Witnessed versus unwitnessed random urine tests in the treatment of opioid dependence.
    Mallya A; Purnell AL; Svrakic DM; Lovell AM; Freedland KE; Gott BM; Sayuk GS; Cicero TJ; Brawer PA; Trafton JA; Scherrer JF; Lustman PJ
    Am J Addict; 2013; 22(2):175-7. PubMed ID: 23414505
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Urine Drug Screening in a Telehealth Setting for the Treatment of Opioid Use Disorder.
    Williams AR; Rowe C; Gallagher R; Aronowitz SV; Diamond-Reivich J; Bisaga A
    JAMA Health Forum; 2023 Jul; 4(7):e232247. PubMed ID: 37505489
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.